Drug intelligence / Profile preview

cholestyramine + gemfibrozil + niacin

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of cholestyramine, gemfibrozil, and niacin used primarily for treating dyslipidemia and metabolic syndrome. This triple drug combination works through multiple mechanisms to improve lipid profiles. Gemfibrozil activates PPARα to increase HDL and reduce triglycerides, niacin influences VLDL metabolism to reduce LDL and increase HDL, and cholestyramine binds bile acids in the intestine to reduce cholesterol absorption. Clinical studies have shown this combination significantly reduces metabolic syndrome components and prevalence when added to lifestyle interventions.

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)HCAR2 (Hydroxycarboxylic acid receptor 2)

Beyond the preview

Go deeper on cholestyramine + gemfibrozil + niacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cholestyramine + gemfibrozil + niacin.

Explore the full profile